Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivesto ABOASMY 26 EV-to-EBIT is 0.55 as of Jul. 24, 2026. GuruFocus rates OASMY with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 690 Drug Manufacturers companies, Vivesto AB ranks worse than 144927.39% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Vivesto AB's Enterprise Value for the quarter that ended in Mar. 2026 was $-3.34 Mil.
Vivesto AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivesto AB EV-to-EBIT Related Terms
Vivesto AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Vivesto AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivesto AB EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Vivesto AB's EV-to-EBIT falls into.
Vivesto AB's current Enterprise Value is $-1.88 Mil.
Vivesto AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivesto AB (OASMY) has a EV-to-EBIT of 0.55 as of Jul. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vivesto AB and its competitors. According to the industry distribution chart, Vivesto AB ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Vivesto AB's EV-to-EBIT too high?
Vivesto AB's current EV-to-EBIT is 0.55. The Drug Manufacturers industry median EV-to-EBIT is 15.46. Vivesto AB's value of 0.55 is 96.4% below this industry median. Based on the distribution chart, Vivesto AB ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vivesto AB ranks #999999 out of 690 companies for EV-to-EBIT. This places Vivesto AB in the lower half of its industry. The industry median EV-to-EBIT is 15.46. Vivesto AB's value of 0.55 is 96.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.46, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivesto AB's current EV-to-EBIT of 0.55 is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vivesto AB and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivesto AB's current EV-to-EBIT is 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OASMY) has a current EV-to-EBIT of 0.55. The current EV-to-EBIT is 0.55 and 96.4% below the Drug Manufacturers industry median of 15.46. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Vivesto AB (OASMY), the current EV-to-EBIT is 0.55 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
26GF Score
Get the complete analysis for OASMY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OASMY has been successfully added to your 
